Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5578MR)

This product GTTS-WQ5578MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5578MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6168MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ9667MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ14235MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ4242MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ401MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ2222MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ2554MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ3609MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW